Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France

Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France

2012 J. Med. Econ

Laas, E. | Vataire, A.L. | Aballea, S. | Valentine, W. | Gligorov, J. | Chereau, E. | Rouzier, R. | Volume: 15, Issue: 6, Pages: 1167-1175, analysis, Female, France, methods, Questionnaires,

OBJECTIVES: There is a paucity of recent data on breast cancer costs, particularly on the burden of chemotherapy. The present study was designed to estimate resource use and costs associated with the current standard of care for adjuvant chemotherapy for breast cancer. METHODS: Costs and resource use were assessed by retrospective analysis of medical records at a single comprehensive cancer care center, Hopital Tenon, Paris, France. Data were extracted from files of female patients having undergone surgical resection of breast cancer between January-July 2010. Patients were included if they received chemotherapy at the hospital and had medical records available. Patients were followed from the start of adjuvant chemotherapy (including pre-chemotherapy) to the end of treatment. Costs were collected for each resource use item from a societal perspective using standard, published sources and expressed in 2011 Euros (euro). Limitations of the analysis included the single-center study design and the use of pre-defined questionnaires on resource use (which may conservatively estimate costs). RESULTS: A total of 62 patients were included in the study with a mean age of approximately 54 years. Most patients had stage II (50.8%) or stage III (40.7%) disease. Anthracycline plus taxane-based chemotherapy regimens were most commonly prescribed (77% of patients). Mean cost of adjuvant chemotherapy was estimated to be approximately euro15,740 per patient from a societal perspective. The acquisition costs of chemotherapy agents were responsible for 26% of the total, with lost productivity (27%), chemotherapy administration (19%), and adverse events (16%) also contributing substantially. CONCLUSIONS: Evaluation of costs in patients with non-metastatic breast cancer in France has shown that the costs of adjuvant chemotherapy are substantial. The main components of total cost were the cost of chemotherapy agents, lost productivity, chemotherapy administration, and management and prevention of adverse events

https://www.doi.org/10.3111/13696998.2012.713414